Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in eosinophilic chronic rhinosinusitis with nasal polyps
jRCT2080224984Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma comparing Benralizumab 30 mg with Placebo (2 arms). Started Dec 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on jRCT2080224984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224984.